R&D | April 15, 2026
Regeneron and Telix strike major radiopharma pact in push into next-gen cancer therapies
The companies plan to advance multiple solid tumor targets from Regeneron’s antibody portfolio
The companies plan to advance multiple solid tumor targets from Regeneron’s antibody portfolio
Policy, regulations, AI and CRDMO take centre stage at the flagship event of the Department of Pharmaceuticals
At India Pharma 2026, Dr Bahl calls for experimentation over imitation as funding rises and translational ecosystem reforms gather pace
Veteran biopharma leader stressed that generic medicines must be viewed separately from biologics
The campaign builds on the three-year partnership unveiled earlier this season
At the centre of this shift is Eli Lilly and Company, whose latest investments in China and Japan are helping redefine the next phase of GLP-1 supply strategy
This event will bring together global stakeholders to explore India’s growing capabilities in pharma and biopharma innovation, research, and manufacturing
The two-day conference and exhibition features discussions on policy frameworks, AI-led drug discovery, next-generation technologies, and global competitiveness
Routine regulatory filing confirms completion of demat and share transfer compliances for March quarter
The presentations will showcase previously undisclosed data highlighting the expanding potential of Actinium’s Ac-225 radiotherapy platform across both solid tumors and hematologic malignancies
Subscribe To Our Newsletter & Stay Updated
